World-leading experts to focus on RSV, a significant public health challenge with an estimated 64 million people of all ages impacted every year1
17 abstracts to evaluate unmet medical need and approaches to RSV prevention in adults
Results include immunogenicity and safety data for GSK’s RSV vaccine
GSK plc (LSE/NYSE: GSK) will share its latest research findings on the respiratory syncytial virus (RSV) at the 13th International RSV Symposium in Iguazu, Brazil (12-15 March). This symposium brings together the world's leading experts in the field to discuss the latest advancements in RSV research, prevention, and treatment.
During the conference, GSK and collaborating experts will present a total of 17 abstracts covering a range of topics, including the epidemiology and burden of RSV, several late-stage clinical read outs on Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted), GSK’s RSV vaccine, cost-effectiveness modelling, and analysis of the potential impact of different circulating RSV strains on the efficacy of GSK’s RSV vaccine.
Susie Barnes, SVP, Head of Global Medical Affairs, Vaccines said: “As a leader in innovation and prevention, we are committed to collaborating with the global scientific community to better understand the challenge of RSV in adults. To date, more than 11 million adults globally have received our RSV vaccine, generating robust data on the impact of immunisation to help improve public health and protect those at risk.”
An estimated 64 million people globally of all ages are impacted by RSV every year, including older adults and those with certain underlying medical conditions.2 Despite RSV vaccines, including GSK’s vaccine, being available in over 60 markets, only a minority of eligible adults have been immunised so far. In the US, about 24% of eligible adults had received a RSV vaccine by the end of the 2023–24 season.3 The International RSV Symposium is an opportunity to present data to strengthen understanding of the risks of RSV in adults and the potential benefits of RSV vaccination amongst healthcare professionals and the scientific community.
Key abstracts to be presented at International RSV Symposium
New data to advance understanding of and improve RSV prevention in adults:
-
AReSVi 004 – 36-month immunogenicity: data from a phase 3 study evaluating immunogenicity and safety following administration of a second dose of GSK’s RSV vaccine 36 months after initial vaccination in adults aged 60 years and older.
-
AReSVi 006 – strains sequencing: using GSK’s AReSVi-006 phase 3 efficacy study, this analysis focuses on the genetic variations of the virus over three RSV seasons and the potential breadth of efficacy of GSK’s RSV vaccine against these variations.
-
AReSVi 006 – patient reported outcomes: results from the analysis of patient-reported data evaluating the impact of RSV infection in vaccinated and non-vaccinated people enrolled over three RSV seasons in the phase 3 efficacy study.
-
NCT05921903 – vaccine dosing in immunocompromised patients: data from a phase 2b study evaluating the immune response and safety of GSK’s RSV vaccine in adults (≥18 years of age) who are immunocompromised due to lung and renal transplant, comparing one versus two doses one month after the second vaccine administration compared to a control group of non-immunocompromised adults aged 50 and above receiving a single dose of GSK’s RSV vaccine.
-
NCT06389487 – vaccine response in adults 18-49 years of age at increased risk of RSV disease: data from a phase 3b study evaluating the non-inferiority of the immune response and safety of GSK’s RSV vaccine in adults aged 18-49 at increased risk for RSV disease compared to adults aged 60 and older.
Full list of GSK presentations at RSV Symposium
About RSV in adults
RSV is a common contagious virus affecting the lungs and breathing passages. Adults can be at increased risk for RSV disease due to certain comorbidities, immune compromised status, or advanced age. RSV can exacerbate conditions, including COPD, asthma, and chronic heart failure and can lead to severe outcomes, such as pneumonia, hospitalisation, and death.4 Each year RSV causes over 465,000 hospitalisations and 33,000 deaths in adults aged 60 and older in high-income countries.5
About GSK’s RSV vaccine
Respiratory Syncytial Virus Vaccine, Adjuvanted, contains recombinant RSV glycoprotein F stabilised in the prefusion conformation (RSVPreF3). This antigen is combined with GSK’s proprietary AS01E adjuvant.
The use of this vaccine should be in accordance with official recommendations. As with any vaccine, a protective immune response may not be elicited in all vaccinees.
The GSK proprietary AS01 adjuvant system contains QS-21 STIMULON adjuvant licensed from Antigenics Inc, a wholly owned subsidiary of Agenus Inc.
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.
References
1.National Institute of Allergy and Infectious Diseases, Respiratory Syncytial Virus (RSV). Available at: https://www.niaid.nih.gov/diseases-conditions/respiratory-syncytial-virus-rsv – last accessed: February 2025
2.National Institute of Allergy and Infectious Diseases, Respiratory Syncytial Virus (RSV). Available at: https://www.niaid.nih.gov/diseases-conditions/respiratory-syncytial-virus-rsv – last accessed: February 2025
3.K. Bajema et al., “Respiratory syncytial virus vaccine effectiveness among US veterans, September 2023 to March, 2024: a target trial emulation study” in The Lancet Infectious Disease, Published Online January 20, 2025 https://doi.org/10.1016/S1473-3099(24)00796-5
4.Centers for Disease Control and Prevention (CDC), RSV in Older Adults, 2024. Available at: https://www.cdc.gov/rsv/older-adults/index.html - Last accessed: September 2024
5.Savic M, et al., “Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: a systematic literature review and meta-analysis”, in Influenza Other Respir Viruses, 2023, 17(1):e13031, DOI: 10.1111/irv.13031